Advenchen 
Welcome,         Profile    Billing    Logout  
 5 Products   33 Diseases   5 Products   1369 Trials   5508 News 


«12...36373839404142434445464748»
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) (clinicaltrials.gov) -  Jul 26, 2018   
    P2,  N=120, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=90 --> 120 | Trial completion date: Apr 2018 --> Dec 2018 | Trial primary completion date: Feb 2018 --> Jun 2018
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Trial completion, Trial primary completion date, Metastases:  Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy (clinicaltrials.gov) -  Apr 23, 2018   
    P2/3,  N=37, Completed, 
    Recruiting --> Active, not recruiting | N=90 --> 120 | Trial completion date: Apr 2018 --> Dec 2018 | Trial primary completion date: Feb 2018 --> Jun 2018 Recruiting --> Completed | Trial primary completion date: Sep 2018 --> Dec 2017
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Enrollment open, Metastases:  A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers (clinicaltrials.gov) -  Mar 20, 2018   
    P2,  N=38, Recruiting, 
    AL3818 shows superior efficacy for the treatment of endometrial cancer irresponsive to conventional carboplatin and paclitaxel combination and warrants further investigation. Not yet recruiting --> Recruiting
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases:  A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) (clinicaltrials.gov) -  Feb 7, 2018   
    P2,  N=118, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2018 --> Dec 2018 | Trial completion date: Aug 2018 --> Jun 2019 | Initiation date: Mar 2017 --> Mar 2017
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open, Trial initiation date:  A Study To Test The Effect Of Apatinib On P450 Enzymes (clinicaltrials.gov) -  Feb 7, 2018   
    P1,  N=20, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2018 --> Dec 2018 | Trial completion date: Aug 2018 --> Jun 2019 | Initiation date: Mar 2017 --> Mar 2017 Not yet recruiting --> Recruiting | Initiation date: Aug 2017 --> Aug 2017
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    New P2 trial, Metastases:  Anlotinib and Irinotecan for Ewing Sarcoma (clinicaltrials.gov) -  Jan 31, 2018   
    P2,  N=22, Recruiting, 
  • ||||||||||  AL2846 / Advenchen, Sino Biopharm
    Trial primary completion date, Metastases:  A Study of AL2846 on Tolerance and Pharmacokinetics (clinicaltrials.gov) -  Jan 5, 2018   
    P1,  N=20, Recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Trial initiation date, Trial primary completion date, Metastases:  APFAO: Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (clinicaltrials.gov) -  Jan 3, 2018   
    P2,  N=37, Recruiting, 
    Trial primary completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Recruiting | Initiation date: Jun 2018 --> Jan 2018 | Trial primary completion date: Jun 2019 --> Sep 2019
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial primary completion date:  Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) (clinicaltrials.gov) -  Dec 29, 2017   
    P2/3,  N=120, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Jun 2018 --> Jan 2018 | Trial primary completion date: Jun 2019 --> Sep 2019 Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial primary completion date:  Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102) (clinicaltrials.gov) -  Dec 29, 2017   
    P2,  N=144, Recruiting, 
    Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Apr 2017 --> Dec 2017
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial primary completion date:  Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) (clinicaltrials.gov) -  Dec 29, 2017   
    P2/3,  N=90, Recruiting, 
    Trial primary completion date: Apr 2017 --> Dec 2017 Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial primary completion date:  Study of Anlotinib in Patients With Gastric Cancer(ALTER0503) (clinicaltrials.gov) -  Dec 29, 2017   
    P2/3,  N=378, Recruiting, 
    Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: May 2017 --> Dec 2017
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion, Trial primary completion date, Metastases:  Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer?ALTER0303? (clinicaltrials.gov) -  Sep 18, 2017   
    P2/3,  N=439, Completed, 
    Trial primary completion date: Jul 2017 --> Dec 2017 Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2017
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    P1 data, Trial primary completion date, Metastases:  A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics (clinicaltrials.gov) -  Sep 18, 2017   
    P1,  N=16, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2017 Trial primary completion date: Apr 2017 --> Dec 2017
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial initiation date:  Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) (clinicaltrials.gov) -  Sep 18, 2017   
    P2,  N=90, Recruiting, 
    Trial primary completion date: Apr 2017 --> Dec 2017 Initiation date: Mar 2017 --> Dec 2017